TickerHumNYSE · Healthcare · Drug Manufacturers—General
Pfizer Inc. (PFE)
As of Nov 11, 4:01 PM ET, Pfizer (PFE) last traded at $29.45, up 0.31% on the day. Its TickerHum research score is 51/100 (average). It reported revenue of $63.62B for the twelve months ending 2026-09-27, up 1.3% year over year.
Ratings
- Valuation: 72/100 — Strongest input: price / sales (ttm) 2.6x. Weakest: price / earnings (ttm) 42.1x.
- Growth: 14/100 — Strongest input: revenue growth (ttm, yoy) +1.3 %. Weakest: diluted eps growth (ttm, yoy) -59.3 %.
- Profitability: 34/100 — Strongest input: net margin 6.3 %. Weakest: return on equity 4.5 %.
- Financial health: 38/100 — Strongest input: long-term debt / equity 0.67. Weakest: cash / long-term debt 0.03.
- Momentum: 64/100 — Strongest input: price vs 200-day average +9.3 %. Weakest: 1-year return +13.8 %.
- Attention: 55/100 — Strongest input: headlines in the last 7 days 64. Weakest: volume vs 3-month average 0.8x.
- Risk resilience: 84/100 — Strongest input: annualised volatility (1y) 21.6 %. Weakest: max drawdown (1y) -17.1 %.
- Data confidence: 97/100 — Strongest input: quote age (hours) 13 h. Weakest: inputs available 90 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $63.62B | TTM ending 2026-09-27 · 10-Q |
| Revenue growth | 1.3% | TTM ending 2026-09-27 · 10-Q |
| Net income | $4.03B | TTM ending 2026-09-27 · 10-Q |
| Diluted EPS | $0.70 | TTM ending 2026-09-27 · 10-Q |
| Net margin | 6.3% | TTM ending 2026-09-27 · 10-Q |
| Free cash flow | $11.79B | TTM ending 2026-09-27 · 10-Q |
| Cash | $1.82B | as of 2026-09-27 · 10-Q |
| Long-term debt | $60B | as of 2026-09-27 · 10-Q |
| Debt / equity | 0.67 | as of 2026-09-27 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000078003).
Comparable companies for Pfizer
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Pfizer vs Merck & Co. (PFE vs MRK) — Same industry (Drug Manufacturers—General); market cap 2.2x; shares: oncology, vaccines
- Pfizer vs Gilead Sciences (PFE vs GILD) — Same industry (Drug Manufacturers—General); market cap 1.3x; shares: oncology
- Pfizer vs Bristol-Myers Squibb (PFE vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.77x; shares: oncology
- Pfizer vs Amgen (PFE vs AMGN) — Same industry (Drug Manufacturers—General); market cap 1.5x; shares: oncology
- Pfizer vs AbbVie (PFE vs ABBV) — Same industry (Drug Manufacturers—General); market cap 3.1x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.